MXPA04002495A - Compuestos de imidazopiridin como moduladores del receptor 5-ht4. - Google Patents

Compuestos de imidazopiridin como moduladores del receptor 5-ht4.

Info

Publication number
MXPA04002495A
MXPA04002495A MXPA04002495A MXPA04002495A MXPA04002495A MX PA04002495 A MXPA04002495 A MX PA04002495A MX PA04002495 A MXPA04002495 A MX PA04002495A MX PA04002495 A MXPA04002495 A MX PA04002495A MX PA04002495 A MXPA04002495 A MX PA04002495A
Authority
MX
Mexico
Prior art keywords
hydrogen
alkyl
halo
arylalkyl
amido
Prior art date
Application number
MXPA04002495A
Other languages
English (en)
Inventor
Stobie Alan
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MXPA04002495A publication Critical patent/MXPA04002495A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Esta invencion proporciona un compuesto de formula (I) (ver formula) o las sales farmaceuticamente aceptables del mismo en el que R1 es hidrogeno, halo o alquilo; R2 y R3 son independientemente hidrogeno, alquilo, alquenilo, alquinilo, aminoalquilo o hidroxialquilo; o R2 y R3 tomados conjuntamente con el atomo de nitrogeno al que estan unidos pueden formar heterociclo; R4 es hidrogeno, halo, acilo, amino, amido, arilo, arilalquilo o heteroarilo; R5 es hidrogeno, halo, alquilo, alquenilo, alquinilo, acilo, amino, amido, arilo, arilalquilo o heteroarilo; R6 es hidrogeno, alquilo o alcoxialquilo; X es NR9 en el que R9 es hidrogeno o alquilo; e Y es (CR7R8)n en el que n es un numero entero entre 0 y 5. Estos compuestos presentan actividad de union al receptor 5-HT4 y son por tanto de utilidad para el tratamiento de enfermedad por reflujo gastroesofagico, dispepsia no ulcerosa, dispepsia funcional, sindrome del intestino irritable o similares en mamiferos, especialmente en seres humanos. Esta invencion tambien proporciona una composicion farmaceutica que comprende el compuesto anterior.
MXPA04002495A 2001-10-22 2002-10-03 Compuestos de imidazopiridin como moduladores del receptor 5-ht4. MXPA04002495A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34337101P 2001-10-22 2001-10-22
US41248502P 2002-09-20 2002-09-20
PCT/IB2002/004098 WO2003035649A1 (en) 2001-10-22 2002-10-03 Imidazopyridine compounds as 5-ht4 receptor modulators

Publications (1)

Publication Number Publication Date
MXPA04002495A true MXPA04002495A (es) 2004-05-31

Family

ID=26993446

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04002495A MXPA04002495A (es) 2001-10-22 2002-10-03 Compuestos de imidazopiridin como moduladores del receptor 5-ht4.

Country Status (9)

Country Link
EP (1) EP1440071B1 (es)
JP (1) JP2005526003A (es)
AT (1) ATE307812T1 (es)
BR (1) BR0213026A (es)
CA (1) CA2461159A1 (es)
DE (1) DE60206952T2 (es)
ES (1) ES2248616T3 (es)
MX (1) MXPA04002495A (es)
WO (1) WO2003035649A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
CA2499494A1 (en) * 2002-09-20 2004-04-01 Pfizer Inc. N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators
DOP2003000703A (es) * 2002-09-20 2004-03-31 Pfizer Compuestos de imidazopiradina como agonistas del receptor 5-ht4
CA2523077A1 (en) * 2003-04-21 2004-11-04 Pfizer Inc. Imidazopyridine compounds having 5-ht4 receptor agonistic activity and 5-ht3 receptor antagonistic activity
DE102004024772A1 (de) * 2004-05-17 2005-12-22 Grünenthal GmbH Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide
WO2005118531A1 (en) * 2004-06-01 2005-12-15 Eli Lilly And Company Aminomethyl-azacycle derivatives as inhibitors of monoamine uptake
JP5160764B2 (ja) * 2006-10-13 2013-03-13 全薬工業株式会社 特定の構造の複素環化合物を含む抗鬱剤、脳保護剤、アミロイドβ沈着抑制剤または老化抑制剤
CA2670636A1 (en) 2006-11-27 2008-06-05 H. Lundbeck A/S Heteroaryl amide derivatives
US8852216B2 (en) 2007-03-23 2014-10-07 Ethicon Endo-Surgery, Inc. Tissue approximation methods
KR20090130109A (ko) * 2007-04-10 2009-12-17 하. 룬트벡 아크티에 셀스카브 Ｐ2ｘ7 길항제로서의 헤테로아릴 아미드 유사체
DK3099675T3 (en) 2013-12-16 2018-05-22 Suven Life Sciences Ltd INDAZOLIC COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS
ES2958391T3 (es) 2014-11-06 2024-02-08 Bial R&D Invest S A Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos
AU2015342887B2 (en) 2014-11-06 2020-09-10 Bial - R&D Investments, S.A. Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
AU2015342883B2 (en) 2014-11-06 2020-07-02 Bial - R&D Investments, S.A. Substituted pyrrolo(1,2-a)pyrimidines and their use in the treatment of medical disorders
CN106146386A (zh) * 2015-04-21 2016-11-23 江苏威凯尔医药科技有限公司 一种制备普卡必利中间体的新工艺
CN109311887B (zh) 2016-04-06 2022-09-13 Bial研发投资股份有限公司 吡唑并[1,5-a]嘧啶基甲酰胺化合物以及它们在治疗医学病症中的用途
CA3020305A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
CA3020310A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
CN109311902B (zh) 2016-05-05 2022-07-15 Bial研发投资股份有限公司 取代的咪唑并[1,2-b]哒嗪、咪唑并[1,5-b]哒嗪、相关化合物及其用途
EP3452455A4 (en) * 2016-05-05 2019-11-13 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO [1,2-] PYRIDINES, SUBSTITUTED IMIDAZO [1,2-] PYRAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF ILLNESSES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260303A (en) * 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
GB9221468D0 (en) * 1992-10-13 1992-11-25 Smithkline Beecham Plc Pharmaceuticals

Also Published As

Publication number Publication date
CA2461159A1 (en) 2003-05-01
BR0213026A (pt) 2004-10-05
DE60206952D1 (de) 2005-12-01
EP1440071A1 (en) 2004-07-28
ATE307812T1 (de) 2005-11-15
DE60206952T2 (de) 2006-06-22
ES2248616T3 (es) 2006-03-16
JP2005526003A (ja) 2005-09-02
WO2003035649A1 (en) 2003-05-01
EP1440071B1 (en) 2005-10-26

Similar Documents

Publication Publication Date Title
MXPA04002495A (es) Compuestos de imidazopiridin como moduladores del receptor 5-ht4.
AR036906A1 (es) Compuestos de imidazopiridin como moduladores del receptor 5-ht4
BRPI0507180A (pt) derivados de 1-isopropil-2-oxo-1,2-diidropiridina-3-carboxamida tendo atividade agonìstica de receptor 5-ht4
MXPA06002880A (es) Derivados 1,1,1-trifluoro-4-fenil-4-metil-2-(1h-pirrolo `2,3-cipiridin-2-ilmetil) pentan-2-ol y compuestos relacionados como ligandos glucorticoides para el tratamiento de enfermedades inflamatorias y diabetes.
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
MXPA05011270A (es) Compuestos de imidazopiridina que tienen actividad agonista del receptor 5-ht4 y actividad antagonista del receptor 5-ht3.
HUP0400828A2 (hu) Kondenzált heterociklikus aminopirimidinek, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
MY135423A (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE60032249D1 (de) AMINO-SUBSTITUIERTE PYRAZOLOi1,5-Aö-1,5-PYRIMIDINE UND PYRAZOLOi1,5-Aö-1,3,5-TRIAZINE
WO2002015662A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
HUP0002461A2 (hu) Triciklusos benzotiepin- vagy benzoxepinszármazékok és ezeket tartalmazó gyógyszerkészítmények
WO2004089366A8 (en) Bicyclic compounds as nr2b receptor antagonists
SI0773943T1 (en) Compounds useful as antiproliferative agents and garft inhibitors
AP1816A (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists.
YU52403A (sh) Heterociklična jedinjenja koja imaju antibakterijsko dejstvo, postupak za njihovo dobijanje i farmaceutske smeše koje ih sadrže
IL174678A0 (en) Arylindenophyridines and arylindenophyrimidines and their use as adenosine a2a receptor antagonist
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
NO20075617L (no) 4-fenyl-5-okso-1,4,5,6,7,8-heksahydrokinolinderivater for behandling av infertilitet
DE69022744D1 (de) Piperidin und pyrrolidin derivate.
MXPA04005151A (es) Compuestos terapeuticos.
MXPA05005340A (es) Nuevos derivados antagonistas del receptor de la vitronectina, sus procedimientos de preparacion, su aplicacion como medicamentos y los compuestos farmaceuticos que los contienen.
NO20020886L (no) Nye integrin- <alfa>v<beta>3-inhibitorer
PE20030538A1 (es) Derivados de gabusectin, procedimientos para su preparacion y su uso
YU28701A (sh) N-(2-(heteroaril)etil)-3-fenilpiperidini, n-(2-(heteroaril) etil)-4-fenilpiperidin i srodna jedinjenja sa supstituentom u položaju 4 piperidinskog prstena